Mount Sinai Dermatology
@MSHSDerm
Followers
970
Following
4K
Media
898
Statuses
2K
Official account of The Kimberly and Eric J. Waldman Department of Dermatology @mountsinainyc. Leaders in dermatological treatment, care, research & education.
New York City
Joined November 2021
We are proud to announce a $5M gift from Clifford S. Asness, PhD, & Laurel Asness to rename our Center of Excellence in Eczema to the Asness Family Center of Excellence in Eczema & Allergic Conditions, w- @EmmaGuttman as Director. Details:
0
1
4
Our Annual report outlines our many achievements in 2024. We delivered comprehensive & superior dermatological care w- more than 118,000 patient visits & conducted groundbreaking, translational research. Details: #WeFindAWay @ichanmountsinai @EmmaGuttman
0
1
1
RT @andrewlji: We are thrilled to share our latest work now published in @CellReports! We combined #scRNAseq and #MERFISH on mouse models o….
0
7
0
RT @CellReports: A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation
cell.com
Imanishi et al. employ murine models of type 2 skin inflammation to uncover a key basophil-fibroblast pro-inflammatory feedforward loop driving pathology. Through single-cell and spatial transcript...
0
4
0
Dr. @andrewlji and colleagues found that while white SOTRs had higher skin cancer incidence, time to diagnosis was similar across races. All patients deserve timely screening—risk is not just about race. 🔗 @emmaguttman
0
0
2
RT @itchdoctor: Congrats @andrewlji on this beautiful translational work to identify novel mechanisms by which basophils and stromal fibrob….
0
3
0
Lebrikizumab rapidly reduced IL-13–driven biomarkers and improved clinical outcomes in moderate-to-severe AD. This study by @emmaguttman and colleagues confirms IL-13 as a central driver of systemic inflammation and a prime target for precision therapy. 🔗
0
1
2
Congratulations to our C2C STAR Raffle Winners! 👏.April Hussain ☀️.Patricia Toro ☀️.Zoan Powell-Brown ☀️.Congratulations to the recipients and thank you to everyone who took time to recognize their colleagues! #teamwork #excellence #jobwelldone #WeFindAWay 🙌 👏 @EmmaGuttman
0
0
0
Congratulations! We are grateful for .Avril Reivers 🌟.Robert Lopez 🌟 .for celebrating 10 years with Mount Sinai. 👏 🙌 .We're truly inspired by their amazing dedication and appreciate the positive impact they make every single day. #jobwelldone @EmmaGuttman @IcahnMountSinai
0
1
1
A global consensus co-authored by @itchdoctor redefines pruritus as a standalone disease, not just a symptom. This new framework guides research, treatment, and policy—marking a shift in how we address chronic itch. 🔗 @emmaguttman
0
0
0
See this video— @EmmaGuttman presenting “Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy” @IcahnMountSinai.
Emma Guttman-Yassky from the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA, presents their research findings published in Allergy: . L. Xi, E. Peeva, Y. Yamaguchi, et al., “Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata.
0
1
1
Topical ruxolitinib 1.5% cream led to marked improvement in a teen with localized morphea unresponsive to steroids. Highlights the potential of JAK inhibition in early, superficial disease. 🔗 @emmaguttman
0
1
2
Nemolizumab led to rapid pruritus relief in a 44-year-old man with refractory lichen amyloidosis—marking the first reported success in a nonatopic PLCA case. IL-31 blockade may hold promise beyond atopic populations. 🔗 @EmmaGuttman
0
1
1
After unsuccessful response w-other treatments, this pt got results on lebrikizumab + 2 months = #eczema success story. @EmmaGuttman & the team at the Asness Family Center of Excellence in Eczema & Allergic Conditions are here to help. Call 212-241-9728.
0
1
1
Tildrakizumab showed comparable efficacy to risankizumab and guselkumab at 28 weeks in plaque psoriasis, with no increased safety risk vs. placebo. Mid-term data like this help guide treatment decisions beyond induction. 🔗@EmmaGuttman
0
1
2
RT @itchdoctor: BAD News: Our joint ADCNI-Cell Symposia is oversubscribed! . GOOD News: We expected this and have the space to continue tak….
0
1
0
Dr. Golant and incoming resident Dr. Ball at @IcahnMountSinai report the first case of extensive cutaneous lichen planus treated successfully with deucravacitinib. Targeted Tyk2 inhibition showed marked clinical improvement in just 2 months.🔗@EmmaGuttman
0
0
0
This #happypatient had success after 5 months of treatment. New treatments are making alopecia areata more manageable & providing hope to our patients. @EmmaGuttman & team @ Alopecia Center of Excellence offer the latest treatments. Call 212-241-HAIR.
0
1
1
Nemolizumab led to rapid, complete resolution of cholestatic pruritus in a PSC patient post-liver transplant after multiple failed therapies, a thought provoking case by Dr. Talia and research fellow Gabriela Soto-Canetti. 🔗 @EmmaGuttman
0
1
2
Keratoacanthoma-like eruptions after pembrolizumab + dupilumab? A new case report by Dr. Gulati and colleagues shows IL triamcinolone led to resolution suggesting reactive hyperplasia, not malignancy. Important insights for cirAE management.🔗@EmmaGuttman
0
1
2
Congratulations! We are grateful for Tomlee L. Abraham, celebrating 20 years w- Mount Sinai. His commitment to excellence is truly inspiring, & we deeply appreciate the leadership that empowers our team to achieve new heights every day. #jobwelldone @EmmaGuttman @icahnmountsinai
0
1
1